Vensica Medical, a ground-breaking urology therapeutics firm based in New York City that the company has secured $11 million in financing that was led by Israel Biotech Fund (IBF) with active participation from Merz and Laborie. The company also expects to apply this funding in achieving its goals of enhancing new urologic treatments.
Strategic Allocation of Funds
The capital is to be used by the company to fund Phase 2 clinical trials for its treatment of OAB in the United States and Europe. Built on the principles of biological activity and using botulinum toxin A (Xeomin®) and the Vensica Group’s unique needle-free system, Vensica offers an invasive OAB treatment for patients.
About Vensica Medical
Located in the incubator of The Trendlines Group, Vensica Medical is managed by its CEO Avner Geva and CTO Avi Eftel. Xeomin® injection can now be conveniently delivered directly into the bladder avoiding the discomfort of needle penetration due to the companies proprietary technology. As a result of this relationship with Merz, Vensica has exclusivity over Xeomin® for needle-free therapeutic application in urology, where Merz has unique clinical development experience.
Important Business Relations and International Setting
Besides the new York executive office, Vensica has a second important operational location in Herzliya in Israel, and it works in synergy especially with The Israel Innovation Authority. With Merz, the company will be in a place to take a leading role in pro minimally invasive urological solutions which present substantial enhancements for OAB and others with the goal of changing the therapeutic gem in urology.
**To get all USA Startup news Please Visit – https://growwseed.com/category/usa-startup-funding-news/
